Mucibrón (Ambroxol Hydrochloride)

Ambroxol, the active ingredient in Mucibrón, is a mucolytic presented as an oral formulation for oral use. It helps to loosen and clear thick respiratory secretions in patients with acute or chronic bronchial conditions, facilitating easier expectoration. It is commonly employed in adults and children who experience productive coughs associated with bronchitis, COPD, asthma, or upper respiratory infections.

GNH USA supplies Mucibrón as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics and health‑care institutions worldwide, ensuring consistent quality and regulatory compliance across regions.

Ambroxol is a mucolytic that acts on respiratory secretions to improve clearance in various bronchial and airway disorders. - Acute bronchitis: reduces mucus viscosity, aiding expectoration and symptom relief. - Chronic bronchitis: facilitates mucus clearance, decreasing cough frequency. - Chronic obstructive pulmonary disease (COPD): improves airway patency by thinning secretions. - Asthma with productive cough: assists in clearing sputum during exacerbations. - Upper respiratory tract infections: helps relieve congestion by promoting mucus drainage.

Ambroxol is generally well tolerated, but some patients may experience adverse reactions.

Common Side Effects: - Nausea - Taste disturbance or bitter taste - Abdominal discomfort or mild diarrhea - Headache - Transient skin rash

Serious or Rare Side Effects: - Allergic reactions including urticaria or angioedema - Severe cutaneous adverse reactions such as Stevens‑Johnson syndrome - Hepatic enzyme elevation or hepatitis - Eosinophilia or other hematologic abnormalities - Anaphylaxis

When using Ambroxol, consider the following safety measures. - Assess renal function: adjust use in severe renal impairment if needed. - Monitor for hypersensitivity: discontinue if rash or swelling occurs. - Use with caution in patients with peptic ulcer disease: may increase gastric irritation. - Avoid concomitant use with other mucolytics unless advised. - Pregnancy and lactation: safety not established; weigh benefits vs risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Ambroxol may interact with certain medicines; review the following categories.

Major Interactions (Avoid): - Antitussive agents containing codeine: may counteract mucolytic effect and increase risk of respiratory depression. - Other mucolytic or expectorant products: additive effect may cause excessive bronchial irritation.

Moderate Interactions (Monitor Closely): - Quinidine: Ambroxol can increase quinidine plasma levels; monitor cardiac effects. - CYP2D6 substrates: potential mild inhibition; observe for altered drug activity. - Bronchodilators: no direct interaction, but monitor clinical response.